Top 5 Medical Companies To Watch In Right Now

Top 5 Medical Companies To Watch In Right Now: FibroGen Inc (FGEN)

FibroGen, Inc. (FibroGen) is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat unmet medical needs. The Company focuses in the areas of fibrosis and hypoxia-inducible factor (HIF) biology. FibroGens products include Roxadustat (FG-4592), which is an oral small molecule inhibitor of HIF prolyl hydroxylases (HIF-PHs), in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and FG-3019, which is a monoclonal antibody in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer and liver fibrosis. The Companys subsidiaries include FibroGen Europe Oy (FibroGen Europe) and FibroGen China Anemia Holdings, Ltd. (FibroGen China).

Roxadustat is the HIF-PH inhibitor in Phase III clinical development, which acts by stimulating the bodys natural pathway of erythropoiesis, or red blood cell produc tion. Roxadustat represents a new paradigm for the treatment of anemia in CKD patients and offers injectable erythropoiesis stimulating agents (ESAs). 1,449 subjects have participated in 26 completed Phase I and II clinical studies for roxadustat in North America, Europe and Asia. The Company, along with its collaboration partners, Astellas Pharma Inc., (Astellas) and AstraZeneca AB,(AstraZeneca), has designed a global Phase III program to support regulatory approval of roxadustat in both NDD-CKD and DD-CKD patients in multiple geographies.

FG-3019 is the Companys fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), a critical common element in the progression of fibrosis and associated diseases. In Phase II IPF clinical studies, FG-3019 demonstrated the stabilization of disease and, in human studies, reversal of lung fibrosis in some patients. In an open-label Phase II pancreatic cancer study of FG-301! 9 plus gemcitabine and erlotinib, FG-3019 demonstrated a dose-depen! dent improvement in one year survival rate. In 10 Phase I and Phase II clinical studies of FG-3019 to date involving over 340 subjects, FG-3019 has been tolerated across a range of doses studied, and there have been no dose-limiting toxicities observed as of November 13, 2014.

The Company competes with Threshold Pharmaceuticals, Inc., Gilead Sciences, Inc., Halozyme Therapeutics, Inc., Gilead Sciences, Inc., Celgene Corporation, Janssen Biotech, Inc., Johnson & Johnson, Inc., Sanofi, Novartis and Biogen Idec.

Advisors' Opinion:

• [By John Udovich]

  Recent IPOFibroGen Inc (NASDAQ: FGEN) surged 22.96% today, reportedly after the journal Hepatology published the results of a workshop between the FDA and the American Association for the Study of Liver Disease (AASLD) which laid out criteria for a phase three study of a treatment for non-alcoholic steatohepatitis (NASH) meaning its worth taking a closer look at the stock along with the performance of potential small cap or mid cap liver disease stock peers like Conatus Pharmaceuticals Inc (NASDAQ: CNAT), Intercept Pharmaceuticals Inc (NASDAQ: ICPT) and Raptor Pharmaceutical Corp (NASDAQ: RPTP) which rose 24.35%, 10.98% and 2.02%, respectively. According to Investors Business Daily, NASH (the more serious version of fatty liver disease) is potentially an enormous market with about 6 millionUS patients but thelack of previous treatments had left it unclear how the FDA would measure success against the disease while FibroGen Inc doesn't yet have a NASH human trial in the works, it has said it hopes to start one for its lead candidate FG-3019 (its in mid-stage trials for pulmonary fibrosis and liver fibrosis due to hepatitis B infection).

source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/top-5-medical-companies-to-watch-in-right-now.html